Transitional epithelium

Apr 15, 2020

FDA Approves First Therapy for Treatment of Low-Grade Upper Tract Urothelial Cancer

Nov 11, 2019

Global Urothelial Carcinoma Market Insights, Epidemiology and Market Forecasts Report 2019-2028

Sep 16, 2019

Seattle Genetics and Astellas Announce U.S. FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application in Locally Advanced or Metastatic Urothelial Cancer

Jul 16, 2019

Astellas and Seattle Genetics Announce Submission of Biologics License Application to FDA for Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer

Jun 04, 2019

RemeGen, Ltd. Announces Positive Results from RC48 Clinical Trial in HER2-Positive Metastatic or Unresectable Urothelial Cancer

Jun 03, 2019

Astellas and Seattle Genetics Announce Antibody-Drug Conjugate Enfortumab Vedotin Produced Tumor Response Rate of 44 Percent in Patients with Most Common Type of Advanced Urothelial (Bladder) Cancer

May 03, 2019

The Italian R&D Excellence at the American Urological Association's 2019 Annual Meeting

Apr 12, 2019

BALVERSA(TM) (erdafitinib) Receives U.S. FDA Approval for the Treatment of Patients with Locally Advanced or Metastatic Urothelial Carcinoma with Certain FGFR Genetic Alterations

Feb 11, 2019

Nektar Therapeutics to Webcast Conference Call with Urothelial Cancer Specialist for Analysts & Investors at the 2019 ASCO Genitourinary Cancers Symposium